aminophylline injection, USP Adverse Reactions

()

ADVERSE REACTIONS

Adverse reactions associated with theophylline are generally mild when peak serum theophylline concentrations are <20 mcg/mL and mainly consist of transient caffeine-like adverse effects such as nausea, vomiting, headache, and insomnia. When peak serum theophylline concentrations exceed 20 mcg/mL, however, theophylline produces a wide range of adverse reactions including persistent vomiting, cardiac arrhythmias, and intractable seizures which can be lethal (see OVERDOSAGE).

Other adverse reactions that have been reported at serum theophylline concentrations <20 mcg/mL include diarrhea, irritability, restlessness, fine skeletal muscle tremors, and transient diuresis. In patients with hypoxia secondary to COPD, multifocal atrial tachycardia and flutter have been reported at serum theophylline concentrations ≥15 mcg/mL. There have been a few isolated reports of seizures at serum theophylline concentrations <20 mcg/mL in patients with an underlying neurological disease or in elderly patients. The occurrence of seizures in elderly patients with serum theophylline concentrations <20 mcg/mL may be secondary to decreased protein binding resulting in a larger proportion of the total serum theophylline concentration in the pharmacologically active unbound form. The clinical characteristics of the seizures reported in patients with serum theophylline concentrations <20 mcg/mL have generally been milder than seizures associated with excessive serum theophylline concentrations resulting from an overdose (i.e., they have generally been transient, often stopped without anticonvulsant therapy, and did not result in neurological residua).

Products containing aminophylline may rarely produce severe allergic reactions of the skin, including exfoliative dermatitis, after systemic administration in a patient who has been previously sensitized by topical application of a substance containing ethylenediamine. In such patients skin patch tests are positive for ethylenediamine, a component of aminophylline, and negative for theophylline. Pharmacists and other individuals who experience repeated skin exposure while physically handling aminophylline may develop a contact dermatitis due to the ethylenediamine component.

Table IV. Manifestations of Theophylline Toxicity* Percentage of Patients Reported With Sign or Symptom
*  These data are derived from two studies in patients with serum theophylline concentrations
>30 mcg/mL. In the first study (Study #1 – Shanon, Ann Intern Med 1993;119:1161-67), data were prospectively collected from 249 consecutive cases of theophylline toxicity referred to a regional poison center for consultation. In the second study (Study #2 – Sessler, Am J Med 1990; 88:567-76), data were retrospectively collected from 116 cases with serum theophylline concentrations >30 mcg/mL among 6000 blood samples obtained for measurement of serum theophylline concentrations in three emergency departments. Differences in the incidence of manifestations of theophylline toxicity between the two studies may reflect sample selection as a result of study design (e.g., in Study #1, 48% of the patients had acute intoxications versus only 10% in Study #2) and different methods of reporting results.
** NR = Not reported in a comparable manner.

Acute Overdose

(Large Single Ingestion)

Chronic Overdosage

(Multiple Excessive Doses)

Sign/Symptom

Study 1

(n=157)

Study 2

(n=14)

Study 1

(n=92)

Study 2

(n=102)

Asymptomatic

       NR**

0

       NR**

6

Gastrointestinal

   Vomiting

 73

  93

 30

 61

   Abdominal pain

       NR**

  21

       NR**

 12

   Diarrhea

       NR**

0

       NR**

 14

   Hematemesis

       NR**

0

       NR**

2

Metabolic/Other

   Hypokalemia

 85

 79

 44

 43

   Hyperglycemia

 98

       NR**

 18

       NR**

   Acid/base disturbance

 34

  21

9

5

   Rhabdomyolysis

      NR**

7

       NR**

0

Cardiovascular

   Sinus tachycardia

  100

  86

  100

 62

   Other supraventricular

2

  21

12

 14

        tachycardias

   Ventricular premature beats

3

 21

 10

 19

   Atrial fibrillation or flutter

1

       NR**

 12

       NR**

   Multifocal atrial tachycardia

0

       NR**

2

       NR**

   Ventricular arrhythmias with

7

 14

 40

0

        hemodynamic instability

   Hypotension/shock

       NR**

  21

       NR**

8

Neurologic

   Nervousness

       NR**

  64

       NR**

 21

   Tremors

 38

  29

 16

 14

   Disorientation

       NR**

7

       NR**

 11

   Seizures

5

  14

 14

5

Death

3

  21

 10

4

Find aminophylline injection, USP medical information:

Find aminophylline injection, USP medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

aminophylline injection, USP Quick Finder

Prescribing Information
Download Prescribing Information

Health Professional Information

Adverse Reactions

ADVERSE REACTIONS

Adverse reactions associated with theophylline are generally mild when peak serum theophylline concentrations are <20 mcg/mL and mainly consist of transient caffeine-like adverse effects such as nausea, vomiting, headache, and insomnia. When peak serum theophylline concentrations exceed 20 mcg/mL, however, theophylline produces a wide range of adverse reactions including persistent vomiting, cardiac arrhythmias, and intractable seizures which can be lethal (see OVERDOSAGE).

Other adverse reactions that have been reported at serum theophylline concentrations <20 mcg/mL include diarrhea, irritability, restlessness, fine skeletal muscle tremors, and transient diuresis. In patients with hypoxia secondary to COPD, multifocal atrial tachycardia and flutter have been reported at serum theophylline concentrations ≥15 mcg/mL. There have been a few isolated reports of seizures at serum theophylline concentrations <20 mcg/mL in patients with an underlying neurological disease or in elderly patients. The occurrence of seizures in elderly patients with serum theophylline concentrations <20 mcg/mL may be secondary to decreased protein binding resulting in a larger proportion of the total serum theophylline concentration in the pharmacologically active unbound form. The clinical characteristics of the seizures reported in patients with serum theophylline concentrations <20 mcg/mL have generally been milder than seizures associated with excessive serum theophylline concentrations resulting from an overdose (i.e., they have generally been transient, often stopped without anticonvulsant therapy, and did not result in neurological residua).

Products containing aminophylline may rarely produce severe allergic reactions of the skin, including exfoliative dermatitis, after systemic administration in a patient who has been previously sensitized by topical application of a substance containing ethylenediamine. In such patients skin patch tests are positive for ethylenediamine, a component of aminophylline, and negative for theophylline. Pharmacists and other individuals who experience repeated skin exposure while physically handling aminophylline may develop a contact dermatitis due to the ethylenediamine component.

Table IV. Manifestations of Theophylline Toxicity* Percentage of Patients Reported With Sign or Symptom
*  These data are derived from two studies in patients with serum theophylline concentrations
>30 mcg/mL. In the first study (Study #1 – Shanon, Ann Intern Med 1993;119:1161-67), data were prospectively collected from 249 consecutive cases of theophylline toxicity referred to a regional poison center for consultation. In the second study (Study #2 – Sessler, Am J Med 1990; 88:567-76), data were retrospectively collected from 116 cases with serum theophylline concentrations >30 mcg/mL among 6000 blood samples obtained for measurement of serum theophylline concentrations in three emergency departments. Differences in the incidence of manifestations of theophylline toxicity between the two studies may reflect sample selection as a result of study design (e.g., in Study #1, 48% of the patients had acute intoxications versus only 10% in Study #2) and different methods of reporting results.
** NR = Not reported in a comparable manner.

Acute Overdose

(Large Single Ingestion)

Chronic Overdosage

(Multiple Excessive Doses)

Sign/Symptom

Study 1

(n=157)

Study 2

(n=14)

Study 1

(n=92)

Study 2

(n=102)

Asymptomatic

       NR**

0

       NR**

6

Gastrointestinal

   Vomiting

 73

  93

 30

 61

   Abdominal pain

       NR**

  21

       NR**

 12

   Diarrhea

       NR**

0

       NR**

 14

   Hematemesis

       NR**

0

       NR**

2

Metabolic/Other

   Hypokalemia

 85

 79

 44

 43

   Hyperglycemia

 98

       NR**

 18

       NR**

   Acid/base disturbance

 34

  21

9

5

   Rhabdomyolysis

      NR**

7

       NR**

0

Cardiovascular

   Sinus tachycardia

  100

  86

  100

 62

   Other supraventricular

2

  21

12

 14

        tachycardias

   Ventricular premature beats

3

 21

 10

 19

   Atrial fibrillation or flutter

1

       NR**

 12

       NR**

   Multifocal atrial tachycardia

0

       NR**

2

       NR**

   Ventricular arrhythmias with

7

 14

 40

0

        hemodynamic instability

   Hypotension/shock

       NR**

  21

       NR**

8

Neurologic

   Nervousness

       NR**

  64

       NR**

 21

   Tremors

 38

  29

 16

 14

   Disorientation

       NR**

7

       NR**

 11

   Seizures

5

  14

 14

5

Death

3

  21

 10

4

Resources

Didn’t find what you were looking for? Contact us.

MI Digital Assistant

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.

Call 800-438-1985*

*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5Pm ET Monday to Friday; excluding holidays.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety

To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.

If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.

FDA Medwatch

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.